Table 4. Comparison of baseline characteristics and outcomes of KTx recipients with IgAN recurrence in the graft versus recipients without IgAN recurrence.
| Parameter | Recipients with IgAN recurrence | Recipients without IgAN recurrence | p-value |
|---|---|---|---|
| N (%), Mean (±SD) or Median (IQR) | N = 23 | N = 73 | |
| Age at IgAN diagnosis (years) | 35.1(10.85) | 33.8 (6.7) | 0.49 |
| Age at KTx (years) | 40.9 (9.6) | 44.15 (10.4) | 0.18 |
| Gender (male) | 17 (73.9) | 51 (69.9) | 0.71 |
| Time from IgAN diagnosis to ESKD (years) | 3.85 (3.3) | 5.97 (7.7) | 0.13 |
| Dialysis duration (months) | 13.06 (34.6) | 39.46 (56.1) | 0.019 |
| Deceased donor | 5 (21.7) | 34 (46.6) | 0.035 |
| Living donor | 18 (78.3) | 39 (53.0) | 0.027 |
| Living (related) donor | 17 (73.9) | 25 (64.1) | 0.46 |
| Donor age (years) | 50.2 (6.1) | 53.3 (7.8) | 0.11 |
| Serum creatinine at recurrence | 2.1(0.8) | - | |
| Serum creatinine end follow up | 1.83 (0.52) | 1.44 (0.45) | 0.0017 |
| Estimated GFR at end of follow up (ml/min/1.73 m2) | 42.05 (15.6) | 53.9 (14.2) | 0.0022 |
| Acute rejection (ever) | 2 (9.5) | 8 (10.95) | 0.84 |
| Graft loss (any cause) | 3 (13.0) | 8 (10.95) | 0.78 |
| Death with functioning graft, any cause | 0 | 4 (5.4) | 0.32 |
| Human leukocyte antigen B35 | 10 (47.6) | 21 (29.2) | 0.11 |
| Human leukocyte antigen B8 | 1 (3.0) | 4 (5.4) | 0.88 |
| Human leukocyte antigen mismatch (all) | 1.9 (0.9) | 2.4 (0.9) | 0.0385 |
| MMF + Tac + GCs | 11 (47.8) | 54 (73.9) | 0.02 |
| MMF + CsA + GCs | 9 (39.1) | 11 (15.05) | 0.01 |
| mTOR + Tac + GCs | 3 (13) | 8 (10.95) | 0.78 |
| Follow up time (months) | 121.4 (49.25) | 97.4 (65.1) | 0.99 |
Abbreviations: IgAN; IgA nephropathy, GFR; glomerular filtration rate, ESKD; end-stage kidney disease, MMF; Mycophenolate mofetil formulation, Tac; tacrolimus, CsA; cyclosporine, GCs; glucocorticoids, mTOR; mammalian target of rapamycin inhibitor.